ONCOLOGY

Ear Toxicity

Sep 8, 2017 by in ONCOLOGY Comments Off on Ear Toxicity

, Ahmad Ameri1 and Mona Malekzadeh2 (1) Department of Clinical Oncology, Imam Hossein Educational Hospital, Shahid Beheshti University of Medical Sciences (SBMU), Shahid Madani Street, Tehran, Iran (2) Department of Radiotherapy and…

read more

Radiation Brain Injury

Sep 8, 2017 by in ONCOLOGY Comments Off on Radiation Brain Injury

, Ahmad Ameri1 and Mona Malekzadeh2 (1) Department of Clinical Oncology, Imam Hossein Educational Hospital, Shahid Beheshti University of Medical Sciences (SBMU), Shahid Madani Street, Tehran, Iran (2) Department of Radiotherapy and…

read more

Hair Loss

Sep 8, 2017 by in ONCOLOGY Comments Off on Hair Loss

, Ahmad Ameri1 and Mona Malekzadeh2 (1) Department of Clinical Oncology, Imam Hossein Educational Hospital, Shahid Beheshti University of Medical Sciences (SBMU), Shahid Madani Street, Tehran, Iran (2) Department of Radiotherapy and…

read more

The Role of PET/CT in Prostate Cancer Management

Aug 19, 2017 by in ONCOLOGY Comments Off on The Role of PET/CT in Prostate Cancer Management

Fig. 5.1 A normal 18F-choline PET scan (MIP image). Physiological uptake of choline is present in the salivary glands, liver, spleen, kidneys, bowel and bladder with low-grade normal bone marrow…

read more

Epidemiology and Clinical Features

Aug 19, 2017 by in ONCOLOGY Comments Off on Epidemiology and Clinical Features

Fig. 1.1 Estimated age-standardised rates (World) per 100,000 [2] Fig. 1.2 Trends in incidence of prostate cancer in selected countries: age-standardised rate (W) per 100,000 [2] Fig. 1.3 The 20…

read more

Pathology of Prostate Cancer

Aug 19, 2017 by in ONCOLOGY Comments Off on Pathology of Prostate Cancer

Fig. 2.1 Immunohistochemistry demonstrates basal cells (stained brown with marker 34betaE12) in benign glands, while the surrounding malignant glands are negative 2.3 Immunohistochemistry The immunostains commonly used are p63 (nuclear…

read more

Management of Prostate Cancer

Aug 19, 2017 by in ONCOLOGY Comments Off on Management of Prostate Cancer

Low-risk prostate cancer All of T1 or T2a, Gleason < 7, PSA < 10 Intermediate-risk prostate cancer Between low- and high-risk groups High-risk prostate cancer Any of T3 or T4, Gleason > 7, PSA > 20 In general…

read more

OpenPET Enabling PET Imaging During Radiotherapy

Aug 19, 2017 by in ONCOLOGY Comments Off on OpenPET Enabling PET Imaging During Radiotherapy

Fig. 4.1 Shows the comparison between a conventional PET detector (a) and the depth-of-interaction (DOI) detector (b). The DOI detector eliminates the parallax error, caused by the thickness of the…

read more
Get Clinical Tree app for offline access